A detailed history of Goldman Sachs Group Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 222,600 shares of YMAB stock, worth $1.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
222,600
Previous 138,739 60.45%
Holding current value
$1.84 Million
Previous $1.68 Million 74.45%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.95 - $15.39 $834,416 - $1.29 Million
83,861 Added 60.45%
222,600 $2.92 Million
Q2 2024

Aug 13, 2024

SELL
$11.6 - $17.25 $2.63 Million - $3.91 Million
-226,797 Reduced 62.05%
138,739 $1.68 Million
Q1 2024

May 15, 2024

SELL
$6.57 - $18.69 $212,966 - $605,836
-32,415 Reduced 8.15%
365,536 $5.94 Million
Q4 2023

Feb 13, 2024

BUY
$4.88 - $7.42 $41,987 - $63,841
8,604 Added 2.21%
397,951 $2.71 Million
Q3 2023

May 14, 2024

SELL
$4.86 - $7.23 $41,815 - $62,206
-8,604 Reduced 2.16%
389,347 $2.12 Million
Q3 2023

Nov 14, 2023

SELL
$4.86 - $7.23 $64,657 - $96,187
-13,304 Reduced 3.3%
389,347 $2.12 Million
Q2 2023

May 14, 2024

BUY
$5.68 - $10.34 $1.2 Million - $2.19 Million
211,860 Added 111.04%
402,651 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$5.68 - $10.34 $1.2 Million - $2.19 Million
211,860 Added 111.04%
402,651 $2.73 Million
Q1 2023

May 14, 2024

SELL
$2.83 - $5.11 $356,752 - $644,171
-126,061 Reduced 39.79%
190,791 $955,000
Q1 2023

May 11, 2023

SELL
$2.83 - $5.11 $356,752 - $644,171
-126,061 Reduced 39.79%
190,791 $955,000
Q4 2022

May 14, 2024

BUY
$3.0 - $15.17 $401,325 - $2.03 Million
133,775 Added 73.07%
316,852 $1.55 Million
Q4 2022

Feb 13, 2023

BUY
$3.0 - $15.17 $401,325 - $2.03 Million
133,775 Added 73.07%
316,852 $1.55 Million
Q3 2022

May 14, 2024

BUY
$13.96 - $19.67 $437,659 - $616,674
31,351 Added 20.66%
183,077 $2.64 Million
Q3 2022

Nov 10, 2022

BUY
$13.96 - $19.67 $437,659 - $616,674
31,351 Added 20.66%
183,077 $2.64 Million
Q2 2022

May 14, 2024

SELL
$8.22 - $15.13 $2.02 Million - $3.73 Million
-246,225 Reduced 61.87%
151,726 $2.3 Million
Q2 2022

Aug 15, 2022

BUY
$8.22 - $15.13 $210,555 - $387,554
25,615 Added 20.31%
151,726 $2.3 Million
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $597,687 - $1.59 Million
-91,250 Reduced 41.98%
126,111 $1.5 Million
Q4 2021

Feb 14, 2022

SELL
$15.51 - $29.31 $9.24 Million - $17.5 Million
-595,994 Reduced 73.28%
217,361 $3.52 Million
Q3 2021

Nov 10, 2021

BUY
$27.47 - $37.31 $22.3 Million - $30.3 Million
813,355 New
813,355 $23.2 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $362M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.